Albemarle Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company reported a fourth quarter 2014 net loss attributable of $18.5 million, or $0.24 per share, compared to fourth quarter 2013 net income attributable to company of $155.9 million, or $1.91 per share. Fourth quarter 2014 adjusted earnings were $77.4 million, or $0.99 per share, compared to $89.3 million, or $1.09 per share, for the fourth quarter of 2013. The Company reported net sales of $598.6 million in the fourth quarter of 2014, down from net sales of $639.6 million in the fourth quarter of 2013, driven mainly by unfavorable currency exchange and pricing impacts across all the businesses, and lower volumes in Performance Chemicals. Operating loss was $23.338 million against operating profit of $227.110 million a year ago. Net loss from continuing operations was $12.990 million or $0.22 per diluted share against net income from continuing operations of $162.232 million or $1.92 per diluted share a year ago. LBITDA was $5.335 million against EBITDA of $254.456 million a year ago. Adjusted EBITDA was $136.833 million against $145.042 million a year ago.

Net income attributable to company for the full year 2014 were $133.3 million, or $1.69 per share, compared to $413.2 million, or $4.90 per share, for the full year 2013. Adjusted earnings for the full year 2014 were $332.1 million, or $4.20 per share, compared to $338.2 million, or $4.01 per share, for the full year 2013. Net sales for the full year 2014 were $2.45 billion, up from $2.39 billion for the full year 2013, driven mainly by favorable Catalyst Solutions pricing and volumes on strong demand, partly offset by lower volumes and pricing in Performance Chemicals and the unfavorable effects of currency exchange. Operating profit was $271.298 million against operating profit of $576.675 million a year ago. Net income from continuing operations was $230.437 million or $2.57 per diluted share against net income from continuing operations of $435.726 million or $4.85 per diluted share a year ago. Capital expenditures were $110.576 million against $155.346 million a year ago. EBITDA was $275.822 million against EBITDA of $688.422 million a year ago. Adjusted EBITDA was $562.155 million against $557.551 million a year ago. Cash flow from operations was approximately $459.2 million for the year ended December 31, 2014, up 6% against the same period in 2013 on lower working capital.